Terazosin Hydrochloride is indicated in:

• Single therapy for relief from signs and symptoms of benign prostatic hyperplasia (BPH)
• Treatment of hypertension

Terazosin hydrochloride is a selective alpha-1 adrenoreceptor competitive blocking agent with a longer duration of action. Terazosin is a quinazoline derivative. It is very rapidly absorbed and exhibits activity within 15 minutes after oral ingestion.

Terazosin is selective for alpha-1-adrenoceptors but not for their individual subtypes. Inhibition of these alpha-1-adrenoceptors results in relaxation of smooth muscle in blood vessels and the prostate, lowering blood pressure and improving urinary flow. Smooth muscle cells account for roughly 40% of the volume of the prostate, and so their relaxation reduces pressure on the urethra. It has also been shown that catecholamines induce factors responsible for mitogenesis, and alpha-1-adrenergic receptor blockers inhibit this effect. A final long-term mechanism of terazosin and other alpha-1-adrenergic receptor blockers is the induction of apoptosis of prostate cells. Treatment with terazosin enhances the expression of transforming growth factor beta-1 (TGF-β1), which upregulates p27ᵏⁱᵖ¹ and the caspase cascade.

Benign Prostatic Hyperplasia

• Initial dose: 1 mg at bedtime is starting dose of all patients and this dose should not be exceeded.
• Subsequent dose: The dose slowly increases to achieve the desired response. The usual recommended dose range is 5-10 mg administered once a day.

Hypertension

• Initial dose: 1 mg at bedtime is starting dose of all patients and this dose should not be exceeded.
• Subsequent dose: The dose slowly increases to achieve the desired response. The usual recommended dose range is 2-10 mg administered once a day.

• In patients receiving Terazosin plus ACE inhibitors or diuretics, the proportion reporting dizziness or related side effects was greater than in the total population of Terazosin-treated patients from clinical trials.
• Terazosin has been given without interaction with analgesics/anti-inflammatory drugs, cardiac glycosides, hypoglycemics, antiarrhythmics, anxiolytics/sedatives, antibacterials, hormones/steroids, and drugs used for gout.

Terazosin is contraindicated in patients known to be hypersensitive to Terazosin or its analogues.

Postural hypotension is the more commonly reported side effect. Dizziness, lack of energy, peripheral edema, urinary frequency, and priapism have been reported.

The safety of Terazosin during pregnancy has not been established. Therefore, Terazosin is not recommended during pregnancy unless the potential benefit justifies the potential risk to the mother and fetus. It is not known whether Terazosin is excreted in breast milk. As many drugs are excreted in breast milk, caution should be exercised when Terazosin is administered to a nursing mother.

• The first dose may cause hypotension (within 30-90 minutes). Therefore, it should be taken on retiring to bed. Caution should be observed when Terazosin is administered with other antihypertensive agents to avoid the possibility of significant hypotension.
• When adding Terazosin to a diuretic or other antihypertensive agent, dosage reduction and retitration may be necessary.
• Patients should be cautioned to avoid situations such as driving and hazardous tasks where injury could result due to syncope after initiation of Terazosin therapy.

Acute overdose may lead to acute hypotension; cardiovascular support is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by keeping the patient in a supine position. At the same time, expansion of plasma volume and noradrenergic vasopressor may also be needed.

Alpha adrenoceptor blocking drugs, BPH / Urinary retention / Urinary incontinence

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.